Ascend Wellness Holdings, Inc.
AAWH$160M
Micro CapNASDAQMedicinal Chemicals & Botanical Products🇺🇸North AmericaMORRISTOWN
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AAWH News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
ASN-002
Basal Cell Carcinoma
Afimoxifene (0.057%) in hydroalcoholic gel
Cyclic Breast Pain, Cyclic Mastalgia
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Hypogonadism
5-FU
Basal Cell Nevus Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ASN-002 | Phase 2 | Basal Cell Carcinoma | - | - |
Afimoxifene (0.057%) in hydroalcoholic gel | Phase 2 | Cyclic Breast Pain, Cyclic Mastalgia | - | - |
Dihydrotestosterone (0.7%) in hydroalcoholic gel | Phase 2 | Hypogonadism | - | - |
5-FU | Phase 2 | Basal Cell Nevus Syndrome | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply